The potential of lunasin extract for the prevention of breast cancer progression by upregulating E-Cadherin and inhibiting ICAM-1

Kusmardi, Kusmardi; Wiyarta, Elvan; Rusdi, Numlil Khaira; Maulana, Andi Muh.; Estuningtyas, Ari; Sunaryo, Hadi

doi:10.12688/f1000research.55385.1

Cited by 5 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A minimum of 100 tumor cells represented each location. The presence of survivin expression was revealed by brown staining of the tumor cell membrane and cytoplasm [15], [16]. Based on the strength of the brown color measured in each field of view using QuPath cell counter, staining intensity was classified as no staining (0), low positive (1+), positive (2+), and high positive (3+) [17].…”

Section: Quantification Of Survivin Expressionmentioning

confidence: 99%

Exploring the Expression of Survivin on Neoadjuvant Chemotherapy in Invasive Breast Carcinoma

Rustamadji

Wiyarta

Anggreani

2022

Open Access Maced J Med Sci

Self Cite

View full text Add to dashboard Cite

Background: Biomarkers are required to monitor the response to neoadjuvant chemotherapy (NC) in patients with invasive breast cancer (IBC). The purpose of this study is to determine the function of Survivin in the administration of NC, both taxane- and non-taxane-based, to patients with IBC. Methods: Thirty-one samples were categorized according to the NC's administrative status (before or after) and the type of NC used (taxane- or non-taxane-based). Age, tumor grade, receptor status (ER, PR, HER2, Ki-67), and survivin expression were evaluated. Survivin expressions were evaluated by IHC staining and categorized according median H-score cut-offs, while other data were collected from archives. Data was gathered and analyzed using generalized linear model. Results: Survivin expression decreased following NC administration, although not significantly (p=0.285). The taxane group had lower survivin expression. Statistically, this was not significant (p=0.329). The non-taxane group had the same outcome (p=0.792). The decline in survivin expression was greater in the taxane group than in the non-taxane group, although it was not statistically significant (p=0.369). Conclusion: Although the changes in survivin expression were not statistically significant, when clinical and laboratory data are analyzed, survivin expression has the potential to be a predictive biomarker of NC response as well as clinical outcome in IBC.

show abstract

Section: Quantification Of Survivin Expressionmentioning

confidence: 99%

Exploring the Expression of Survivin on Neoadjuvant Chemotherapy in Invasive Breast Carcinoma

Rustamadji

Wiyarta

Anggreani

2022

Open Access Maced J Med Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…The staining technique is followed by Primariadewi et al (2021) and Kusmardi et al (2021) (8,(19)(20)(21)(22). According to typical protocols, a paraffin slice of a breast cancer specimen was deparaffinized in xylol (Merck, Jakarta, Indonesia) and rehydrated in 96%, 70% absolute alcohol series (Merck, Jakarta, Indonesia) and distilled water for 5 minutes.…”

Section: Slide Preparation and Ihc Stainingmentioning

confidence: 99%

Exploring the Integrated Role of AKT2, CD44v6, And MT1-MMP as Predictors of Axillary Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type

2022

View full text Add to dashboard Cite

Scan to discover onlineBackground & Objective: Invasive breast carcinoma of no special type (IBC-NST) is the most common type of breast cancer, which mainly causes axillary lymph-node metastasis (ALNM). Building on our previous research, we wanted to explore the optimal combination of AKT2, CD44v6, and MT1-MMP for the ALNM prediction. Methods:The presence or absence of ALNM was used to separate 46 paraffin blocks containing IBC-NST primary tumors into two groups. Age, tumor grade, tumor size, receptor status (ER, PR, HER2, Ki-67, TOP2A), and test biomarker expression were evaluated. Biomarker expressions were assessed by IHC staining and categorized according to their respective cut-offs from our previous study, while other data were collected from archives. Data was gathered and analyzed using univariate, multivariate, and AUROC models. Results:The expression of CD44v6 (OR: 12.77, 95% CI: 2.18-87.12, P=0.005) was identified as the independent variable for ALNM. Meanwhile, AKT2 expression (OR: 3.22, 95% CI: 0.36-22.41, P=0.237) and MT1-MMP expression (OR: 5.35, 95% CI: 0.83-34.54, P=0.078) did not demonstrate a statistically significant independent association in respect to ALNM. Combining AKT2 and MT1-MMP on CD44v6 increased overall accuracy by 4% compared to CD44v6 alone (AUROC 0.89 vs. 0.85). Conclusion:The combined usage of AKT2, CD44v6, and MT1-MMP revealed no significant change compared to CD44v6 alone. Due to the cost and practicality, we propose using CD44v6 as a predictor biomarker of ALNM in IBC-NST.

show abstract

A Concise Review on the Role of Natural and Synthetically Derived Peptides in Colorectal Cancer

Das

Deka

Banerjee

et al. 2022

CTMC

View full text Add to dashboard Cite

Colorectal cancer being the second leading cause of cancer-associated deaths, it has become a significant health concern around the globe. Though there are various counts of cancer treatment approaches, many of them show adverse effects and further compromise the condition of the cancer patients. Hence, significant exertions are conducted for the evolution of a novel biological therapeutic approach with better efficacy and minimal side effects. Current research suggests that the application of peptides in colorectal cancer therapeutics holds the possibility of a emerging anticancer reagent. The primary beneficial factors of peptides are their comparatively rapid and easy process of synthesis and the enormous potential for chemical alterations that can be evaluated for designing novel peptides and enhancing the delivery capacity of peptides. Peptides might be utilized as agents with cytotoxic activities or as a carrier of a specific drug or cytotoxic agents that can efficiently target the tumor cells. Further, peptides can also be used as a tool for diagnostic purposes. The recent analysis aims at developing peptides that have the potential to efficiently target the tumor moieties without harming the nearby normal cells. Additionally, decreasing the adverse effects, and unfolding the other therapeutic properties of potential peptides, are also the subject matter of in-depth analysis. This review provides a concise summary of the function of both natural and synthetically derived peptides in colorectal cancer therapeutics that are recently being evaluated and their potent applications in the clinical field.

show abstract

The potential of lunasin extract for the prevention of breast cancer progression by upregulating E-Cadherin and inhibiting ICAM-1

Cited by 5 publications

References 48 publications

Exploring the Expression of Survivin on Neoadjuvant Chemotherapy in Invasive Breast Carcinoma

Exploring the Expression of Survivin on Neoadjuvant Chemotherapy in Invasive Breast Carcinoma

Exploring the Integrated Role of AKT2, CD44v6, And MT1-MMP as Predictors of Axillary Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type

A Concise Review on the Role of Natural and Synthetically Derived Peptides in Colorectal Cancer

Contact Info

Product

Resources

About